Bioxytran, Inc.
BIXT
$0.04
$0.000.84%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.08% | -41.57% | -58.37% | -45.48% | -20.48% |
| Depreciation & Amortization | 45.57% | 30.68% | -3.30% | -20.41% | -4.82% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.90% | -37.00% | -53.37% | -48.82% | -41.47% |
| Operating Income | 16.90% | 37.00% | 53.37% | 48.82% | 41.47% |
| Income Before Tax | 10.79% | 12.19% | 28.49% | 25.31% | 46.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.79% | 12.19% | 28.49% | 25.31% | 46.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -100.00% | -100.00% | -85.27% |
| Net Income | 10.29% | 11.02% | 27.01% | 24.04% | 46.02% |
| EBIT | 16.90% | 37.00% | 53.37% | 48.82% | 41.47% |
| EBITDA | 17.12% | 37.21% | 53.50% | 48.89% | 41.56% |
| EPS Basic | -26.78% | -51.74% | -16.59% | -1.01% | 44.21% |
| Normalized Basic EPS | -10.00% | -57.39% | -23.29% | -6.22% | 30.69% |
| EPS Diluted | -26.78% | -51.74% | -16.59% | -1.01% | 44.21% |
| Normalized Diluted EPS | -10.00% | -57.39% | -23.29% | -6.22% | 30.69% |
| Average Basic Shares Outstanding | -34.35% | -41.43% | -36.38% | -15.88% | 4.30% |
| Average Diluted Shares Outstanding | -34.35% | -41.43% | -36.38% | -15.88% | 4.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |